This week's study movement
Enrollment, deviations, documents, monitoring findings, SAEs, vendor work, Site blockers, and evidence aging stay visible without a status-deck rebuild.
Biotech
Lean Sponsor oversight for CRO-heavy studies.
Review enrollment movement, vendor actions, site blockers, SAE context, and inspection exposure before the next board update, agency meeting, or pivotal-readiness review.
Lean Sponsor control
Outsourced trial work, Sponsor-owned proof.Lean Sponsor control
A small clinical team still has to defend the trial.
A biotech CMO or head of clinical operations needs to defend Sponsor control even when execution sits with CROs, Sites, labs, EDC, eTMF, safety, and reporting vendors.
CRO-heavy execution
CRO actions, Sponsor review, vendor-system source, Site source, and acceptance history stay distinct.
Board and agency question
Can the CMO explain what changed this week, which vendor action needs Sponsor acceptance, and which evidence matters in the next agency or board conversation?
Pivotal scale
The operating model has to survive pivotal scale.
The jump from one asset to a global pivotal trial exposes weak process: manual trackers, undocumented vendor decisions, late eTMF completeness, and safety context that arrives after leadership needed it.
Repeatable study model
Activation, access review, integrations, eTMF completeness, monitoring, amendments, safety review, and inspection evidence can repeat across studies.
Board and agency answers
Leadership can connect enrollment, safety, deviations, amendments, site readiness, and document evidence before a board or FDA meeting.
Pivotal readiness question
Can the model grow from one asset to a global pivotal? Which evidence will matter in the next agency interaction?
Vendor stack
Biotech teams need visibility without replacing every tool.
Most biotechs already select EDC, eTMF, labs, safety, identity, CRO, and reporting vendors. Clinistack makes ownership, review status, and validation evidence visible without pretending one suite owns every source system.
Record ownership
Each system keeps explicit ownership while Clinistack carries source context, run history, review status, and operational evidence.
Selective rollout
Start with the workstream under pressure: oversight, CTMS, eTMF, integrations, AI review, or inspection readiness.
Vendor governance question
Which system owns the record? Which vendor action needs Sponsor review? Which migration needs validation evidence?
First rollout
Bring the study question your team keeps rebuilding.
We will review the product path, system context, owners, evidence, and rollout approach that fit the trial work in front of you.